Phase-Based Progress Estimates
Johns Hopkins, Baltimore, MDHIVDD HST-NEETs - Biological
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new HIV therapy that uses T-cells from a donor. The trial will study the safety and effectiveness of this new therapy in people who have had a bone marrow transplant.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 3 years

3 years
The HIV reservoir measurements
The feasibility of manufacturing of DD HST-NEETs
45 days
Any ≥ Grade 3 Adverse Events (as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0)

Trial Safety

Trial Design

1 Treatment Group

Donor Derived HIV-Specific T-cells (DD HST-NEETs)
1 of 1

Experimental Treatment

8 Total Participants · 1 Treatment Group

Primary Treatment: DD HST-NEETs · No Placebo Group · Phase 1

Donor Derived HIV-Specific T-cells (DD HST-NEETs)
Experimental Group · 1 Intervention: DD HST-NEETs · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years

Who is running the clinical trial?

Catherine BollardLead Sponsor
13 Previous Clinical Trials
342 Total Patients Enrolled
Richard Ambinder, MD, PhDPrincipal InvestigatorJohns Hopkins University
Michael Keller, MDPrincipal InvestigatorCNMC
3 Previous Clinical Trials
115 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 27 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many participants are currently receiving treatment in this experiment?

"Affirmative. Data hosted on clinicaltrials.gov verifies that this research venture, which was first created on May 1st 2020, is actively recruiting participants. 8 people need to be sourced from two distinct medical centres." - Anonymous Online Contributor

Unverified Answer

Has the Drug and Food Administration sanctioned DD HST-NEETs for medical use?

"Our assessment at Power placed DD HST-NEETs on the lower end of safety, with a score of 1. This reflects this protocol's Phase 1 status, which suggests limited data to support both efficacy and security." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies available for this research project?

"The clinical trial is open for enrollment, as attested to by the records on clinicaltrials.gov from its inception date of May 1st 2020 up until March 2nd 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.